- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.07. | I-Mab buys Bridge Health for $3M-plus to strengthen pivot to CLDN18.2 bispecific | ||
| 17.07. | Novartis' B cell-depleting antibody fails to show promise in phase 2 dermatology study | ||
| 16.07. | Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning | ||
| 16.07. | Otsuka inks $613M deal for Swedish biotech's autoimmune antibodies | ||
| 16.07. | Okyo sets sights on first approval in neuropathic eye pain after phase 2 win | ||
| 16.07. | Alphabet's SandboxAQ teams up with Swiss biotech to develop mRNA cancer vaccine | ||
| 16.07. | NIH fires exec amid probe into wife's role in $3.3M contract: report | ||
| 16.07. | Kezar sees hepatitis hold lifted, hints at resurrecting lupus program | ||
| 16.07. | Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm | ||
| 16.07. | AstraZeneca's AL amyloidosis drug fails to reduce mortality in phase 3 test | ||
| 15.07. | GSK telegraphs 'very limited number' of job cuts amid R&D investment spree | ||
| 15.07. | HHS terminates employees after Supreme Court allows reduction in force to proceed | ||
| 15.07. | Sellas' CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study | ||
| 15.07. | Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M | ||
| 15.07. | Hengrui's GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push | ||
| 15.07. | Acumen taps JCR's blood-brain barrier tech for $555M Alzheimer's deal | ||
| 14.07. | China biotechs 'reshaping' US biopharma as outlicensing deals rise 11%: Jefferies report | ||
| 14.07. | Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials | ||
| 14.07. | Research non-profit to acquire embattled Essa in Xoma Royalty-backed deal | ||
| 14.07. | Takeda's narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing | ||
| 14.07. | AstraZeneca's $1.3B bet on CinCor's blood pressure med appears to pay off with phase 3 win | ||
| 11.07. | Relmada terminates license agreement for troubled phase 3 depression asset | ||
| 11.07. | Karyopharm lays off more workers as hunt for strategic alternatives turns up short | ||
| 11.07. | FDA rejects Capricor's DMD cell therapy, asks for more data | ||
| 10.07. | FDA releases 'initial batch' of more than 200 drug rejection letters |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .